The Top 5 Biosimilar Articles for the Week of January 3

Here are the top 5 biosimilar articles for the week of January 3, 2022.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of January 3, 2022.

Number 5: The top legal stories in biosimilars over the past year concerned etanercept and adalimumab biosimilars and access to insulin.

Number 4: Savings from adalimumab biosimilars, which won't enter the US market until 2023, account for a significant share of the total, investigators said.

Number 3: Patients with stage IV nonsquamous non–small cell lung cancer (NSCLC) demonstrated equivalent outcomes when treated with MYL-1402O or Avastin.

Number 2: With an FDA approval for a second insulin glargine biosimilar, the stage is set for stronger competition in 2022 with potential improved access and savings for patients.

Number 1: Biosimilars have produced more than $20 billion of savings in Europe, but more use of these agents is needed.

To read all of these articles and more, visit centerforbiosimilars.com.